GlassScriptPhysician profile
Andrew Robert Grudzinski
NPI 1285602151
$5,434.43
in general payments reported to CMS, 2019-2025
34 companies · $395 in 2025
The $395 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $954 · 2020: $311 · 2021: $668 · 2022: $1,232 · 2023: $1,068 · 2024: $807 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,269.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $1,040.96 | 2019-2022 | |
| Astellas Pharma US INC | $608.37 | 2019-2024 | Myrbetriq, Veozah, Xtandi |
| Boston Scientific Corporation | $550.41 | 2019-2025 | Moses, Rezum Generator, Lithovue |
| Sumitomo Pharma America, INC. | $525.12 | 2023-2025 | Gemtesa, Orgovyx |
| Abbvie INC. | $408.16 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $314.25 | 2021-2024 | Provenge |
| Telix Pharmaceuticals | $248.99 | 2024-2025 | Illuccix |
| Myriad Genetic Laboratories, INC. | $230.13 | 2021-2023 | Prolaris |
| Myovant Sciences INC. | $165.92 | 2021-2022 | |
| Janssen Biotech, INC. | $150.51 | 2021-2025 | Erleada |
| Teleflex LLC | $142.93 | 2022 | |
| Neotract INC. | $121.97 | 2019 | |
| Pfizer INC. | $113.30 | 2022-2025 | |
| Urogen Pharma, INC. | $101.81 | 2022-2024 | Jelmyto |
| Urovant Sciences INC | $97.77 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $84.28 | 2021-2024 | Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $71.72 | 2021-2022 | |
| Allergan, INC. | $55.03 | 2021-2022 | |
| 180 Medical, INC. | $44.20 | 2022 | |
| Merck Sharp & Dohme LLC | $43.44 | 2023-2024 | Keytruda, Lynparza, Welireg |
| Alnylam Pharmaceuticals INC. | $43.06 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $39.70 | 2021-2024 | Xiaflex |
| Amgen INC. | $38.13 | 2022-2023 | Xgeva |
| Tolmar Pharmaceuticals, INC. | $35.92 | 2021-2022 | |
| Axonics, INC. | $33.78 | 2024 | Bulkamid, Axonics |
| Hollister Incorporated | $28.36 | 2022 | |
| Procept Biorobotics Corporation | $19.85 | 2024 | Aquabeam System |
| Shionogi INC | $18.70 | 2022 | |
| Medtronic, INC. | $15.45 | 2023 | Interstim |
| Astrazeneca Pharmaceuticals LP | $14.80 | 2023 | Imfinzi |
| Cycle Pharmaceuticals INC | $13.95 | 2024 | Tiopronin |
| Kowa Pharmaceuticals America, INC. | $13.46 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,124.48 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Grudzinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.